Pinealon
A short tripeptide studied for neuroprotective and cognitive-enhancing properties, part of the Khavinson peptide bioregulator family.
Pinealon is a three-amino-acid peptide (Glu-Asp-Arg) from the Russian Khavinson programme, sold for memory, focus and brain protection. The name is misleading: when its own developers tested it on pineal gland tissue, it did nothing, while the sibling peptide Epithalon worked — and no study of Pinealon has ever measured melatonin. The real research is about protecting neurons from low oxygen, where it did perform best of the four peptides tested, and about dendritic spines in an Alzheimer's model. There are no randomized or placebo-controlled trials in people, and the one study in older patients found it worked less well than its sibling vesugen and reported signs of inhibited blood-cell production.
What is Pinealon?
Pinealon is a tripeptide (Glu-Asp-Arg) developed by Vladimir Khavinson as part of his peptide bioregulator research. Despite the name, the pineal connection is the weakest part of its story: when Khavinson's own group tested Glu-Asp-Arg alongside Ala-Glu-Asp-Gly (Epithalon) in organotypic pineal gland culture, only Epithalon stimulated pinealocyte proliferation and CGRP synthesis, and melatonin itself has never been measured in any Pinealon study. What the published work actually concerns is neuronal rather than pineal tissue — protection against hypoxia, effects on dendritic spines, and cortical serotonin. As a short peptide it is claimed to be absorbed orally and to reach brain tissue, though neither has been confirmed by pharmacokinetic study.
What Pinealon Is Investigated For
Pinealon is a Khavinson tripeptide (Glu-Asp-Arg) marketed for cognitive enhancement and mental clarity, neuroprotection, melatonin and pineal-axis support, and general anti-aging brain function. One of those four should be set aside at the outset: the pineal and melatonin claim has no Pinealon-specific support at all, and the originating group's own pineal-culture experiment found that Epithalon stimulated pinealocytes while Glu-Asp-Arg did not. The preclinical support — rat hypoxia-protection studies, cell-viability protection from oxidative stress, and a small Russian clinical trial in truck drivers reporting reduced neurotic disorders — is concentrated essentially entirely within the Khavinson research program and has not been independently replicated by Western laboratories under modern trial-methodology standards. The proposed mechanism of direct DNA-regulatory-region interaction by a tripeptide is contested in Western literature, oral bioavailability of intact short peptides has not been pharmacokinetically confirmed, and no blinded randomized controlled trials exist in humans for any cognitive or longevity endpoint. Russian dietary-complex registration is not equivalent to Western drug approval. Claims of cognitive enhancement, neuroprotection, and longevity exceed what the single-program evidence can independently support — treat it as a theoretical bioregulator, not an established nootropic.
History & Discovery
Pinealon emerged from Vladimir Khavinson's bioregulator program at the St. Petersburg Institute of Bioregulation and Gerontology in the 1990s and 2000s, as part of a deliberate strategy to identify minimal-length active sequences from larger tissue-derived peptide preparations. Where Epithalon (Ala-Glu-Asp-Gly) was the group's pineal tetrapeptide, Pinealon (Glu-Asp-Arg) represents a separate tripeptide claimed to target neuronal and pineal-axis tissue with comparable or distinct effects. The amino acid sequence is short enough that the Khavinson group proposes direct cell-membrane penetration and DNA-regulatory-region interaction as the primary mechanism — a mechanistic claim that is contested in Western literature. The published preclinical and clinical record for Pinealon is concentrated almost entirely within the Khavinson research program and a small set of Russian clinical collaborators. Studies report neuroprotection in rat hypoxia models, cell-viability protection from oxidative stress, and a small clinical trial in Russian truck drivers reporting reduced neurotic disorders. Independent Western replication of these findings is essentially absent, and the broader scientific community has not converged on the mechanistic framework that the Khavinson group proposes for short-peptide gene regulation.
How It Works
Pinealon is believed to support brain health by influencing gene expression in brain cells. As a tiny peptide, it can reach the brain and may help protect neurons under stress such as low oxygen. The name points at the pineal gland, but that is the one thing the research does not show: in the originating group's own pineal tissue experiment, Pinealon had no effect on pinealocytes while its sibling peptide Epithalon did.
Pinealon (Glu-Asp-Arg) is proposed to penetrate cells and interact with DNA, modulating gene expression related to neuronal survival and differentiation. The gene lists often attached to it come from molecular docking of promoter binding sites rather than measured expression, and two findings cut against the antioxidant framing: in vitro, the short peptides including pinealon showed no direct antioxidant activity and actually raised the steady-state level of intracellular reactive oxygen species, while still reducing the proportion of dead cells. The better-evidenced neuronal effect is structural — in mouse hippocampal neurons under amyloid synaptotoxicity, 200 ng/ml of the EDR tripeptide increased mushroom spines by 71% and restored them to normal levels. The pineal claim implied by the name is not supported. In organotypic pineal gland culture from 3-month-old rats, Khavinson and colleagues reported that Ala-Glu-Asp-Gly (Epithalon) and Lys-Glu-Asp stimulated the proliferation marker Ki-67 and that CGRP synthesis by pinealocytes was stimulated by Ala-Glu-Asp-Gly only; Glu-Asp-Arg affected neither, and no Pinealon study has measured melatonin. The nearest adjacent finding is in brain cortex rather than pineal tissue, where Glu-Asp-Arg has been reported to stimulate serotonin expression in aging cortical cultures.
Evidence Snapshot
Human Clinical Evidence
Limited, and not in the population usually claimed. There are no randomized or placebo-controlled trials. The main cited study examined 150 male lorry drivers of mean age 43.3 against 150 metal craftsmen, and its peptide arm reported improved psychoemotional indices — with the best effect from pinealon combined with vezugen rather than from pinealon alone. A separate 32-person study in patients aged 41 to 83 with polymorbidity and organic brain syndrome found vesugen outperformed pinealon, and reported prooxidant activity on chemiluminescence together with a fall in circulating CD34-positive cells that the authors read as significant inhibition of haemopoiesis. A smaller occupational study gave pinealon alone as a 100 microgram capsule twice daily for two weeks. No study has measured a cognitive endpoint in an elderly cohort on pinealon monotherapy.
Animal / Preclinical
Moderate. Cell culture and animal studies demonstrate neuroprotective effects.
Mechanistic Rationale
Moderate. Gene regulation by short peptides is an active area of research with some supporting evidence.
Research Gaps & Open Questions
What the current literature has not yet settled about Pinealon:
- 01Independent replication outside the Khavinson research program — neuroprotection, cell-viability, and clinical findings have not been reproduced by Western laboratories under modern trial-methodology standards.
- 02Blinded randomized controlled trials in humans for cognitive enhancement, neuroprotection, or any longevity endpoint.
- 03Pharmacokinetics in humans — absorption (particularly oral and sublingual bioavailability of the intact peptide), distribution, blood-brain-barrier penetration, and clearance have not been characterized.
- 04Mechanism specificity — the proposed mechanism of direct DNA-regulatory-region interaction by a tripeptide is contested in Western literature and has not been independently confirmed.
- 05Long-term safety with cumulative repeated courses, including any effects on neurogenesis-related malignancy risk.
- 06Theoretical cancer-promotion concern — agents that stimulate cell proliferation or modulate gene expression in CNS tissue raise class concerns for tumor-promotion risk in patients with subclinical or remote-history CNS malignancy that have not been adequately addressed.
Forms & Administration
Pinealon is available as oral capsules or sublingual tablets. Treatment courses are typically 10-30 days and may be repeated periodically.
Dosing & Protocols
The ranges below reflect protocols commonly discussed in the literature and by clinicians — not a prescription. Actual dosing for any individual should be determined by a qualified healthcare provider who knows the patient.
Typical Range
There is one published human oral dose: a Russian occupational study gave locomotive-brigade workers one capsule containing 100 mcg of Pinealon twice daily for two weeks. Forum and vendor protocols otherwise describe 100–200 mcg per dose for injectable forms. Capsule and sublingual products from Russian Khavinson-affiliated manufacturers typically deliver low milligram-range doses formulated for slow release through mucosal absorption. There is no published independent dose-finding study.
Frequency
Daily administration across a short course — typically morning dosing for injectable forms, or 1–2 capsules daily for oral forms.
Timing Considerations
No specific timing requirements: can be administered at any time of day, with or without food, and is not tied to exercise timing. Consistency matters more than the specific clock — dose at roughly the same time each day (or same day each week, for weekly protocols) to keep exposure steady.
Cycle Length
10–30 day courses are the standard Khavinson protocol, repeated every 3–6 months — a characteristic feature of Khavinson bioregulator schedules.
Protocol Notes
Injectable research-chemical Pinealon is supplied as lyophilized powder requiring reconstitution in bacteriostatic water; subcutaneous injection is the most commonly described route. Russian Khavinson-affiliated capsule and sublingual products are sold as dietary peptide complexes rather than registered pharmaceuticals. Western clinicians do not generally prescribe it; protocols outside Russia rely on convention and forum consensus rather than anchored clinical guidance. Bioavailability of any oral short peptide is uncertain — the Khavinson group's claims of intact-peptide absorption from oral or sublingual routes have not been confirmed by independent pharmacokinetic study.
Claims for cognitive enhancement, neuroprotection, and longevity exceed what the evidence base, dominated by single-program research, can independently support. Not FDA-approved. Russian protocols come from a single-lab tradition not validated by Western-standard trials. Research-chemical injectable supply is not authorized for human use, and Russian dietary-complex products are not equivalent to approved Western medicines.
Timeline of Effects
Onset
Not characterized in controlled studies. Russian clinical reports describe cognitive parameter changes within the duration of a 10–20 day course. Subjective effects on alertness or sleep, when reported by users, are typically described within the first week of a course.
Peak Effect
Khavinson protocols measure outcomes at the end of a 10–30 day course and at follow-up. There is no characterized peak curve from controlled studies; users typically infer it from convention.
After Discontinuation
No documented withdrawal or rebound. Subjective effects, when reported, fade over weeks of cessation, which is the rationale for the periodic-repeat-course schedule. Long-term cumulative effects from repeated courses across years have not been independently studied.
Common Questions
Does Pinealon affect melatonin or the pineal gland?
There is no evidence that it does, despite the name. The clearest test came from Khavinson's own group, who applied several short peptides to cultured rat pineal gland tissue: Epithalon (Ala-Glu-Asp-Gly) stimulated the proliferation marker Ki-67 and was the only peptide to stimulate CGRP synthesis by pinealocytes, while Glu-Asp-Arg — Pinealon — did neither. Melatonin itself has never been measured in any Pinealon study. The nearest adjacent finding is in a different tissue: Glu-Asp-Arg has been reported to stimulate serotonin expression in aging brain cortex cultures, and serotonin is melatonin's precursor, but cortical serotonin is not pineal melatonin synthesis. If the pineal axis is what you are after, Epithalon is the peptide in this family with the pineal data.
What are peptide bioregulators?
Peptide bioregulators are short peptides (2-4 amino acids) developed by Russian scientist Vladimir Khavinson. They are theorized to regulate gene expression in specific tissues. Pinealon targets brain and pineal gland tissue.
Can Pinealon be taken orally?
Yes. Due to its small size (only 3 amino acids), Pinealon can be absorbed orally, which is a significant advantage over larger peptides that require injection.
Who Pinealon Is NOT For
- •Pregnancy — no adequate reproductive toxicology data; not recommended.
- •Breastfeeding — no data on transfer or infant effects.
- •Active or recent-history central nervous system malignancy — neurogenesis-stimulating agents are theoretically concerning in CNS tumor contexts and warrant oncology clinician evaluation.
- •Active seizure disorder — neuromodulatory short peptides have not been adequately studied for seizure-threshold effects; caution warranted.
- •Pediatric use — no safety or developmental data; not recommended.
- •Known hypersensitivity to peptide preparations or to excipients. Research-chemical supply quality and unknown sterility raise injection-site infection risk absent from clinic-supplied medication.
Drug & Supplement Interactions
Documented clinical drug interactions for Pinealon are essentially absent; no formal interaction studies meeting Western standards have been published. Theoretical class concerns include: concurrent use with serotonergic medications, MAOIs, or other psychotropics has not been studied and could plausibly alter neurotransmitter handling given the proposed neuromodulatory mechanism. Concurrent use with anticonvulsants is unstudied. Combination with other Khavinson bioregulators in longevity stacks is common in forum culture but has not been formally evaluated for interaction safety. Patients on any regular medication, particularly psychiatric, neurological, or oncology-related treatments, should disclose Pinealon use to their prescribing clinician.
Safety Profile
Common Side Effects
Cautions
- • Limited Western clinical data
- • Not FDA-approved
- • Most research from Russian institutions
- • A 32-person study in patients aged 41 to 83 reported prooxidant activity on chemiluminescence and a fall in circulating CD34-positive haematopoietic cells that the authors read as significant inhibition of haemopoiesis — the same paper found no effect on chromatin condensation and judged the peptides safe at the nuclear genetic level, and recommended them explicitly as a non-antioxidant type of geroprotector
- • In the same study vesugen outperformed pinealon, and in two rat studies cortexin had the more pronounced effect on free-radical processes and caspase-3 activity — pinealon is not the strongest agent in its own comparisons
What We Don't Know
Western validation of Khavinson's peptide bioregulator research is limited. Independent replication of results is needed.
Legal Status
United States
Not FDA-approved for any indication. Not recognized as a dietary supplement ingredient. Not on the FDA's list of peptides eligible for 503A compounding. Injectable forms sold primarily through research-chemical suppliers not authorized for human use. Capsule forms from Russian Khavinson-affiliated brands are sometimes imported informally; legitimate clinical access pathways are essentially absent.
International
Russian Khavinson-affiliated capsule and sublingual products are marketed as dietary peptide complexes (not pharmaceuticals) under the Peptides.ru and similar brands. Limited availability through informal CIS distribution. Not approved by EMA, MHRA, Health Canada, or TGA.
Sports & Competition
Not specifically named on the WADA Prohibited List. No governmental health authority has approved Pinealon for human therapeutic use (the Russian capsules are sold as dietary peptide complexes, not medicines), so it can reasonably be read as falling under WADA's S0 class for non-approved substances, which covers the substance in any form, oral or injectable. Athletes subject to WADA code should treat it as prohibited at all times.
Regulatory status changes over time. Verify current local rules with a qualified professional.
Myths & Misconceptions
Myth
Pinealon is the pineal gland peptide, so it supports melatonin and sleep.
Reality
The name is the only pineal thing about it. Khavinson's group tested Glu-Asp-Arg side by side with Ala-Glu-Asp-Gly in organotypic pineal culture and reported that only Ala-Glu-Asp-Gly — Epithalon — stimulated pinealocyte proliferation and CGRP synthesis; Glu-Asp-Arg affected neither. No study of Pinealon has measured melatonin in any species. The published work concerns neurons rather than pinealocytes: protection against hypoxia, dendritic spine restoration in an amyloid model, and serotonin expression in brain cortex. If you are reasoning from the name to a sleep or melatonin effect, nothing in the literature supports that step.
Myth
Independent research has confirmed Pinealon's neuroprotective and cognitive effects.
Reality
Very little. Nearly all efficacy data traces to the Khavinson research program and a small set of Russian clinical collaborators. Western laboratories have not independently replicated the core findings under modern trial-methodology standards.
Myth
Because Pinealon is small enough to take orally, it is well-absorbed and reaches the brain intact.
Reality
Oral bioavailability of intact short peptides is uncertain in general, and Pinealon-specific human pharmacokinetic data — including blood-brain-barrier penetration of intact peptide — has not been published in independent studies. The Khavinson group's claim of intact absorption is not anchored to Western-standard pharmacokinetic confirmation.
Myth
Russian dietary-complex registration means Pinealon is approved as a medicine.
Reality
Russian Khavinson-affiliated capsule products are marketed as dietary peptide complexes, not as registered pharmaceuticals. This is a different regulatory category with lower evidence requirements than prescription-medicine approval, and it is not equivalent to approval by EMA, FDA, MHRA, or other Western regulatory bodies.
Myth
Vladimir Khavinson won the Nobel Prize for peptide bioregulator research.
Reality
He did not. Persistent online attributions are inaccurate. The Khavinson group has published extensively, but the body of work has not been recognized at that level by the broader scientific community, and core program claims have not been independently replicated.
Myth
A tripeptide is too small to have meaningful biological effect, so Pinealon is essentially placebo.
Reality
This is the opposite extreme of the previous myth and also wrong. Short peptides can have real biological activity — the question is not whether such activity is theoretically possible but whether the specific claims for Pinealon's mechanism and effect sizes are supported by independent evidence. The honest answer is that Pinealon may have effects, but the existing evidence does not establish them at a Western trial-methodology standard.
Published Research
14 studiesEDR Peptide: Possible Mechanism of Gene Expression and Protein Synthesis Regulation Involved in the Pathogenesis of Alzheimer’s Disease
Role of Mono- and Divalent Ions in Peptide Glu-Asp-Arg-DNA Interaction
Tripeptides Restore the Number of Neuronal Spines under Conditions of In Vitro Modeled Alzheimer's Disease
[Pinealon and Cortexin influence on behavior and neurochemical processes in 18-month aged rats within hypoxia and hypothermia]
[Effect of synthetic peptides on aging of patients with chronic polymorbidity and organic brain syndrome of the central nervous system in remission]
[Regulation of content of cytokines in blood serum and of caspase-3 activity in brains of old rats in model of sharp hypoxic hypoxia with Cortexin and Pinealon]
[The peptide correction of neurotic disorders among professional truck-drivers]
Effect of short peptides on expression of signaling molecules in organotypic pineal cell culture
The experiment that undercuts the name. Khavinson and colleagues applied short peptides to organotypic pineal gland culture from 3-month-old rats: Ala-Glu-Asp-Gly (Epithalon) and Lys-Glu-Asp stimulated the proliferation marker Ki-67, and CGRP synthesis by pinealocytes was stimulated by Ala-Glu-Asp-Gly alone. Glu-Asp-Arg — Pinealon — did neither. Their own conclusion names Epithalon, not Pinealon, as the peptide that tissue-specifically stimulates pinealocytes. No Pinealon study has measured melatonin.
[Analysis of some parameters of biological age and adaptation possibilities of workers of locomotive brigades]
Pinealon protects the rat offspring from prenatal hyperhomocysteinemia
Penetration of short fluorescence-labeled peptides into the nucleus in HeLa cells and in vitro specific interaction of the peptides with deoxyribooligonucleotides and DNA
The actual evidence for the cell-penetration and DNA-binding mechanism the page describes, which was previously asserted without it. Fluorescein-labelled pinealon produced marked fluorescence in the cytoplasm, nucleus and nucleolus of HeLa cells, and in vitro the peptides quenched labelled deoxyribooligonucleotides to different degrees depending on their own sequence, discriminating between nucleotide sequences and even recognising cytosine methylation state. Note what it is not: HeLa cells and naked oligonucleotides, not neurons and not chromatin in situ.
Pinealon increases cell viability by suppression of free radical levels and activating proliferative processes
[Biological activity of regulatory peptides in model experiments in vitro]
[Investigation of antihypoxic properties of short peptides]
Kozina, Adv Gerontol 2008 — the clearest statement of what the hypoxia work actually found. Across vilon, epitalon, vesugen and pinealon in hypobaric hypoxia, Pinealon had the most pronounced antihypoxic effect, and the authors attribute it not to inhibiting the rise in reactive oxygen species but to stimulating the cell's own antioxidant enzymes and possibly limiting NMDA excitotoxicity. This replaced an earlier citation that PubMed carries without an abstract and does not index as a pinealon study.
Popular Stacks Including Pinealon
Quick Facts
- Class
- Bioregulator Peptide
- Tier
- D
- Evidence
- Preliminary
- Safety
- Limited Data
- Updated
- Nov 2026
- Citations
- 14PubMed
Also known as
Tags
Peptide Families
Related Goals
Conditions Discussed
Evidence Score
Clinical Trials
View Clinical TrialsLinks to ClinicalTrials.gov for reference. Listing does not imply endorsement.